Piper Sandler Maintains Overweight on Structure Therapeutics, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and raises the price target from $58 to $93.
October 26, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Structure Therapeutics and raised the price target from $58 to $93.
The news is directly related to Structure Therapeutics and is likely to have a positive impact on its stock price. The increase in price target by Piper Sandler, a reputable financial firm, indicates a strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100